Sciformix to Present New Change Management Model for Regulatory Operations Outsourcing at DIA EDM 2014
Sciformix Corporation will unveil a change management model for outsourcing regulatory operations and eCTD submissions at this year’s DIA EDM meeting, which will take place in Washington, DC on 22–24 September 2014.
The new outsourced model will allow life science companies who make regulatory submissions electronically to reap significant cost savings and improved compliance through increased efficiencies in the end-to-end submission processes via optimised resource management and process standardization.
Before embarking on an outsourcing partnership, companies need to establish a few critical processes such as setting up an appropriate governance structure; appointing a relationship manager; establishing a proactive way of managing feedback between the partners; and agreeing on parameters such as costs, processes and timelines so a transparent and collaborative environment is established. Partners need to establish how outcomes will be measured relative to the client's needs, be that service-level metrics or deliverables.
The model designed to address these critical processes in the context of regulatory operations will be presented by Darryl Clarke, Director of Regulatory Operations at Sciformix, at the Omni Shoreham Hotel in Washington, DC 23 September at 3:30pm. The presentation, entitled ‘Change management — Outsourcing Regulatory Operations and eCTD Submissions’ will outline the change management model, the reasoning behind companies looking to outsource their regulatory operations, and the concerns the industry has with regards to the internal user adoption of employing an outsourcing partner. The presentation will go on to provide best practices of how companies are successfully integrating outsourcing in regulatory operations.
Mr Clarke, commented: “It is no secret that with the ever-tightening and dynamic regulatory landscape, maintaining efficient and compliant regulatory operations is of paramount importance across the life science industry. Companies must have the ability to change and operationalise processes quickly to remain compliant. Regulatory change presents a significant challenge to life science companies, specifically small to mid-sized companies operating in emerging markets with limited technology and infrastructure. In addition, large companies now require new processes and expertise to manage full audit trails and compliance.”
He continued: “Embracing change management is critical to success in this fast-paced environment, and together with enabling cost savings through process standardization and increased efficiencies, this change management model for outsourcing regulatory operations will provide flexible and cost effective means of managing the peaks and valleys in regulatory submissions.”
Following the success of last year’s combined EDM and ERS/eCTD event, DIA EDM 2014 will continue to explore evolving global trends in e-records, systems and e-content in the clinical and regulatory space. The rapid evolution of global electronic initiatives necessitates industry to continually assess internal processes to maximise content reuse and streamline efforts by pushing submission-ready content and data standards farther upstream. This conference serves as a forum for discussion of emerging standards and processes for submission creation and maximum use of regulatory information.
Related News
-
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Pharma Supply Chain People Moves
The latest appointments, promotions, and structural changes across the pharmaceutical supply chain. -
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement. -
News BIOSECURE Act continues to loom over Chinese pharma manufacturers
With the US BIOSECURE Act on its way to passing into legislation, Chinese companies are facing declining revenues within the first half of 2024 as US pharmaceutical and healthcare companies pull their businesses from the country. -
News Ophthalmologic drug product Eylea faces biosimilar threats after FDA approvals
Regeneron Pharmaceutical’s blockbuster ophthalmology drug Eylea is facing biosimilar competition as the US FDA approves Biocon’s Yesafili and Samsung Bioepis/Biogen’s Opuviz. -
News ONO Pharmaceutical expands oncology portfolio with acquisition of Deciphera
ONO Pharmaceutical, out of Japan, is in the process of acquiring cancer-therapy maker Deciphera Pharmaceuticals for US$2.4 billion. -
News First offers for pharma from Medicare drug price negotiations
Ten high-cost drugs from various pharma manufacturers are in pricing negotiations in a first-ever for the US Medicare program. President Biden’s administration stated they have responded to the first round of offers. -
News Eli Lilly’s Zepbound makes leaps and bounds in weight-loss drug market
In the last week, Eli Lilly has announced their partnership with Amazon.com’s pharmacy unit to deliver prescriptions of Zepbound. Zepbound has also surpassed Novo Nordisk’s Wegovy for the number of prescriptions for the week of March 8.&nbs...
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance